+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bronchitis - Pipeline Review, H2 2019

  • ID: 4861695
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 129 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Incyte Corp
  • MORE
Bronchitis - Pipeline Review, H2 2019

Summary

The Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Bronchitis - Pipeline Review, H2 2019, provides an overview of the Bronchitis (Respiratory) pipeline landscape.

Bronchitis is an inflammation of the lining of bronchial tubes, which carry air to and from lungs. Symptoms include cough that produces mucus (sputum), which may be blood streaked, shortness of breath aggravated by exertion or mild activity, frequent respiratory infections that worsen symptom, wheezing, fatigue, ankle that affects both sides and headaches. Risk factors include smoking, low resistance and gastric reflux.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Bronchitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Bronchitis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bronchitis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 1, 6, 4, 3, 5 and 1 respectively.

Bronchitis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bronchitis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Bronchitis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bronchitis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bronchitis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bronchitis (Respiratory)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bronchitis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bronchitis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca Plc
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Incyte Corp
  • MORE
Introduction
Bronchitis - Overview
Bronchitis - Therapeutics Development
Bronchitis - Therapeutics Assessment
Bronchitis - Companies Involved in Therapeutics Development
Bronchitis - Drug Profiles
Bronchitis - Dormant Projects
Bronchitis - Discontinued Products
Bronchitis - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Bronchitis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Bronchitis - Pipeline by AstraZeneca Plc, H2 2019
Bronchitis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Bronchitis - Pipeline by Daewon Pharmaceutical Co Ltd, H2 2019
Bronchitis - Pipeline by DBV Technologies SA, H2 2019
Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Bronchitis - Pipeline by Han Wha Pharma Co Ltd, H2 2019
Bronchitis - Pipeline by Icure Pharmaceutical Inc, H2 2019
Bronchitis - Pipeline by Incyte Corp, H2 2019
Bronchitis - Pipeline by Merck & Co Inc, H2 2019
Bronchitis - Pipeline by Onspira Therapeutics Inc, H2 2019
Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2019
Bronchitis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Bronchitis - Pipeline by Sam-A Pharm Co Ltd, H2 2019
Bronchitis - Pipeline by Therabron Therapeutics Inc, H2 2019
Bronchitis - Pipeline by Zambon Co SpA, H2 2019
Bronchitis - Dormant Projects, H2 2019
Bronchitis - Dormant Projects, H2 2019 (Contd..1), H2 2019
Bronchitis - Discontinued Products, H2 2019

List of Figures
Number of Products under Development for Bronchitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Daewon Pharmaceutical Co Ltd
  • DBV Technologies SA
  • F. Hoffmann-La Roche Ltd
  • Han Wha Pharma Co Ltd
  • Icure Pharmaceutical Inc
  • Incyte Corp
  • Merck & Co Inc
  • Onspira Therapeutics Inc
  • Orbis Biosciences Inc
  • Regeneron Pharmaceuticals Inc
  • Sam-A Pharm Co Ltd
  • Therabron Therapeutics Inc
  • Zambon Co SpA
Note: Product cover images may vary from those shown
Adroll
adroll